20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Health Canada has approved the use of Moderna Inc's (NASDAQ:MRNA) mRNA COVID-19 vaccine, Spikevax, in a two-dose series of 25 µg per dose in children six months to 5 years.
- Positive interim results from the Phase 2/3 KidCOVE study, announced in March, showed a robust neutralizing antibody response in the 6-month to 5 years of age group.
- The antibody titers in the pre-specified six-month to 23-month and two to 5 years of age sub-groups met the statistical criteria.
- Related: Moderna's Bivalent COVID-19 Booster Shows Antibody Response Against Omicron Subvariants.
- Preliminary efficacy analysis during the Omicron wave showed similar efficacy estimates against Omicron in the 6-month to 5 years.
- European Medicines Agency added extensive swelling of the vaccinated limb in the EU product information as a side effect of Spikevax.
- Price Action: MRNA shares are down 7.18% at $158.91 during the market session on the last check Thursday.
- Photo by mufidpwt via Pixabay
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!